EU Regulator's Enthusiasm for Revamped Pharmacovigilance Database Tempered By Industry Concerns
Executive Summary
Following the launch of the revamped EudraVigilance database last November, a senior EU regulator believes these are exciting times to be involved in the pharmacovigilance arena. Companies, however, are struggling with the additional burden introduced by the new system and have suggested several improvements.
You may also be interested in...
UK Regulator Promises Reasonable and Pragmatic Approach For EudraVigilance Inspections
Aware that marketing authorization holders are still finding their way around the EU’s revamped pharmacovigilance database – a UK inspector explains what procedures and processes companies should have in place to show compliance with new requirements to monitor and report safety signals.
Pharma Frustrated With Revamped EudraVigilance Database
Pharmaceutical companies say they are wasting resources having to scan through high volumes of individual case safety reports in the revamped EU pharmacovigilance database, most of which do not relate to their products.
Pharma's Well-Intentioned 'Improvements' To ICSRs Causing Problems In EudraVigilance
EU marketing authorization holders are unknowingly duplicating individual case safety reports in the revamped EudraVigilance database, a senior regulator warns.